← Leaderboards
Sathy Venkat Balu-Iyer
State University Of New York At Buffalo
$6,910,696
Attributed
$8,462,383
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,462,383 · 3
By mechanism
R01$7,341,214 · 2
R61$1,121,169 · 1
Top collaborators
- Jason G Kay4 shared
- Elizabeth Wohlfert4 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Jason G Kay$3,443,379
- Elizabeth Wohlfert$3,392,353
Others in their field
Top investigators on “Lipids”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Alan M Fogelman · University Of California Los Angeles$57,458,120
- Paul M. Ridker · Brigham And Women'S Hospital$56,179,451
- Adrian Hernandez · Duke University$50,769,596
- Garret A Fitzgerald · University Of Pennsylvania$50,340,498
- Richard A Gibbs · Baylor College Of Medicine$49,140,324
Research focus
LipidsPropertyHemophilia AFactor ViiiProteinsImmune ResponseTherapeutic ProteinMediatingBaseParticleDesignDendritic CellsPreventImmunogenicityPhosphatidylserinesResponseAntibodiesComplicationImmunogenicReplacement TherapyDensityIn VivoGenerationsAntigens
Grant awards (22)
Lipid mediated oral tolerance$931,012
R01 · FY2025 · AI · contact PI
Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A$545,700
R61 · FY2024 · HL · contact PI
Lipid mediated oral tolerance$465,506
R01 · FY2024 · AI · contact PI
Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A$575,469
R61 · FY2023 · HL · contact PI
Lipid mediated oral tolerance$465,506
R01 · FY2023 · AI · contact PI
Lipid mediated oral tolerance$465,506
R01 · FY2022 · AI · contact PI
HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics$395,109
R01 · FY2019 · HL · contact PI
HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics$395,244
R01 · FY2018 · HL · contact PI
HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics$395,380
R01 · FY2017 · HL · contact PI
HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics$395,508
R01 · FY2016 · HL · contact PI
Development and pharmacology of novel lipidic rAHF$391,340
R01 · FY2014 · HL · contact PI
Development and pharmacology of novel lipidic rAHF$380,035
R01 · FY2013 · HL · contact PI
Development and pharmacology of novel lipidic rAHF$399,070
R01 · FY2012 · HL · contact PI
Development and pharmacology of novel lipidic rAHF$413,574
R01 · FY2011 · HL · contact PI
Development and Pharmacology of Novel Lipidic rAHF$271,422
R01 · FY2010 · HL · contact PI
Development and Pharmacology of Novel Lipidic rAHF$271,422
R01 · FY2009 · HL · contact PI
Development and Pharmacology of Novel Lipidic rAHF$271,422
R01 · FY2008 · HL · contact PI
Development and Pharmacology of Novel Lipidic rAHF$271,422
R01 · FY2007 · HL · contact PI
Development and Pharmacology of Novel Lipidic rAHF$193,315
R01 · FY2005 · HL
Development and Pharmacology of Novel Lipidic rAHF$190,380
R01 · FY2004 · HL
Development and Pharmacology of Novel Lipidic rAHF$190,094
R01 · FY2003 · HL
Development and Pharmacology of Novel Lipidic rAHF$188,947
R01 · FY2002 · HL